{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:47:51Z","timestamp":1790887671925,"version":"4.1.0"},"reference-count":33,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. Despite the implementation of the treat-to-target (T2T) strategy and the introduction of several classes of biologic and targeted synthetic disease-modifying antirheumatic drugs (b\/tsDMARDs), a considerable proportion of patients continues to exhibit active, refractory disease. In 2021, the European Alliance of Associations for Rheumatology (EULAR) defined this condition as Difficult-to-Treat Rheumatoid Arthritis (D2T-RA). This study aimed to identify clinical, laboratory, and therapeutic factors associated with D2T-RA. Methods: A total of 344 patients with established RA were retrospectively evaluated. Among them, 164 fulfilled the 2021 EULAR criteria for D2T-RA (D2T group), while 180 did not (NO-D2T group). Clinical (age, sex, disease duration, BMI, smoking, comorbidities), laboratory (RF, ACPA, ESR, CRP), clinimetric (DAS28, CDAI, PhGA, PGA, HAQ), and therapeutic data (glucocorticoid use, methotrexate treatment and dose, monotherapy, advanced therapy exposure, number of failed advanced therapies, current DMARD regimen) were analyzed. Results: Factors significantly associated with D2T-RA included female sex, longer disease duration, higher RF and ACPA titers, elevated ESR levels, glucocorticoid therapy, and a greater number of failed advanced therapies. Although both groups achieved low disease activity or remission by DAS28 and CDAI, JAK inhibitors\u2014particularly Filgotinib and Upadacitinib\u2014were significantly more common in the D2T cohort and appeared associated with clinical stabilization. Conclusions: This study strengthens the understanding of the predictive profile of D2T-RA, confirming the role of disease chronicity and persistent inflammation in the development of treatment resistance. Importantly, the observed trend toward clinical stabilization achieved under JAK inhibitor therapy reinforces their potential to address unmet therapeutic needs in D2T-RA, providing a mechanistically grounded strategy for patients refractory to conventional and biologic DMARDs.<\/jats:p>","DOI":"10.3390\/jpm16020065","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:56:34Z","timestamp":1769684194000},"page":"65","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors Associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA): Real-World Evidence from a Single-Center Cross-Sectional Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8180-6660","authenticated-orcid":false,"given":"Maurizio","family":"Benucci","sequence":"first","affiliation":[{"name":"Rheumatology Unit, S. Giovanni di Dio Hospital,  Azienda USL Toscana Centro, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Li Gobbi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, S. Giovanni di Dio Hospital,  Azienda USL Toscana Centro, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5009-1161","authenticated-orcid":false,"given":"Emanuele Antonio Maria","family":"Cassar\u00e0","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, S. Giovanni di Dio Hospital,  Azienda USL Toscana Centro, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-2445","authenticated-orcid":false,"given":"Riccardo","family":"Terenzi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, S. Giovanni di Dio Hospital,  Azienda USL Toscana Centro, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cioffi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, S. Giovanni di Dio Hospital,  Azienda USL Toscana Centro, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"D\u2019Elia","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Aliberti","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2722-6475","authenticated-orcid":false,"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Department of Experimental and Clinical Medicine, University of Florence, 50121 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1091","authenticated-orcid":false,"given":"Edda","family":"Russo","sequence":"additional","affiliation":[{"name":"Clinical Pathology S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Lari","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Azienda USL Toscana Centro, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Grossi","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Azienda USL Toscana Centro, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6200-4467","authenticated-orcid":false,"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Azienda USL Toscana Centro, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Manfredi","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Azienda USL Toscana Centro, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: Results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: An area of unmet clinical need","volume":"57","author":"Jacobs","year":"2018","journal-title":"Rheumatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/25785826.2021.1928383","article-title":"Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: The KURAMA cohort","volume":"45","author":"Watanabe","year":"2022","journal-title":"Immunol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s10067-019-04579-1","article-title":"Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis","volume":"38","author":"Batko","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/rheumatology\/keac114","article-title":"Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: A narrative review with systematic literature search","volume":"61","author":"Roodenrijs","year":"2022","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/rheumatology\/keac563","article-title":"Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: A multicentre cohort study","volume":"62","author":"Giollo","year":"2023","journal-title":"Rheumatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/rmdopen-2020-001511","article-title":"Diagnostic issues in difficult-to-treat rheumatoid arthritis: A systematic literature review informing the EULAR recommendations","volume":"7","author":"Roodenrijs","year":"2021","journal-title":"RMD Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-023-08975-z","article-title":"Tumor necrosis factor alpha inhibitors and cardiovascular risk in rheumatoid arthritis","volume":"65","author":"Luciano","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1093\/rheumatology\/keac134","article-title":"Comorbidities or extra-articular manifestations: Time to reconsider the terminology?","volume":"61","author":"Dey","year":"2022","journal-title":"Rheumatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13075-021-02560-5","article-title":"Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data","volume":"23","author":"Messelink","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/rheumatology\/kead143","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital","volume":"62","author":"Hecquet","year":"2023","journal-title":"Rheumatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13075-020-02354-1","article-title":"Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis","volume":"22","author":"Plasencia","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Benucci, M., Gobbi, F.L., Cassar\u00e0, E.A.M., Marigliano, A.L., Mannoni, A., and Benvenuti, E. (2025). Single-center cross-sectional analysis of patients with RA, SpA, and PsA: Data from the prescription database. J. Pers. Med., 15.","DOI":"10.3390\/jpm15080366"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An ACR\/EULAR collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Watanabe, R., Okano, T., Gon, T., Yoshida, N., Fukumoto, K., Yamada, S., and Hashimoto, M. (2022). Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1049875"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Takanashi, S., and Kaneko, Y. (2024). Unmet needs and current challenges of rheumatoid arthritis: Difficult-to-treat and late-onset RA. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247594"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s10067-022-06307-8","article-title":"Predictors of remission in rheumatoid arthritis patients treated with biologics: A systematic review and meta-analysis","volume":"41","author":"Khader","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.3899\/jrheum.091432","article-title":"Disease progression and treatment responses in a prospective DMARD-naive seropositive early RA cohort: Does gender matter?","volume":"37","author":"Jawaheer","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3899\/jrheum.080724","article-title":"The influence of sex on patients with rheumatoid arthritis in a large observational cohort","volume":"36","author":"Iikuni","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice","volume":"60","author":"Takanashi","year":"2021","journal-title":"Rheumatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-023-03165-w","article-title":"Unveiling difficult-to-treat rheumatoid arthritis: Long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry","volume":"25","author":"Jung","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-024-03432-4","article-title":"Obesity and fibromyalgia are associated with difficult-to-treat rheumatoid arthritis independent of age and gender","volume":"27","author":"Luciano","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Togashi, T., Ishihara, R., Watanabe, R., Shiomi, M., Yano, Y., Fujisawa, Y., Katsushima, M., Fukumoto, K., Yamada, S., and Hashimoto, M. (2025). Rheumatoid factor: Diagnostic and prognostic performance and therapeutic implications in rheumatoid arthritis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051529"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/annrheumdis-2022-222370","article-title":"Interferon-\u03b1-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming","volume":"81","author":"Cooles","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Iwasaki, T., Watanabe, R., Ito, H., Fujii, T., Okuma, K., Oku, T., Hirayama, Y., Ohmura, K., Murata, K., and Murakami, K. (2022). Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.901437"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s00296-023-05349-8","article-title":"Difficult-to-treat rheumatoid arthritis in a comprehensive evaluation program: Frequency according to different objective evaluations","volume":"43","author":"Mareco","year":"2023","journal-title":"Rheumatol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00296-022-05124-1","article-title":"Clinical characteristics and variants that predict prognosis of difficult-to-treat rheumatoid arthritis","volume":"42","author":"Yoshii","year":"2022","journal-title":"Rheumatol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ruiz-Lim\u00f3n, P., Mena-V\u00e1zquez, N., Moreno-Indias, I., Lisbona-Monta\u00f1ez, J.M., Mucientes, A., Manrique-Arija, S., Redondo-Rodriguez, R., Cano-Garc\u00eda, L., Tinahones, F.J., and Fern\u00e1ndez-Nebro, A. (2025). Gut dysbiosis is associated with difficult-to-treat rheumatoid arthritis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1497756"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e002842","DOI":"10.1136\/rmdopen-2022-002842","article-title":"Difficult-to-treat rheumatoid arthritis: Clinical issues at early stages of disease","volume":"9","author":"Leon","year":"2023","journal-title":"RMD Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1093\/rheumatology\/keae325","article-title":"Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis","volume":"64","author":"Takanashi","year":"2025","journal-title":"Rheumatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","article-title":"Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: From the FIRST Registry","volume":"24","author":"Ochi","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40744-025-00747-9","article-title":"Effective second-line b\/tsDMARDs for patients with rheumatoid arthritis unresponsive to first-line therapy: Data from the FIRST Registry","volume":"12","author":"Kanda","year":"2025","journal-title":"Rheumatol. Ther."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/65\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:20:08Z","timestamp":1770049208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jpm16020065"],"URL":"https:\/\/doi.org\/10.3390\/jpm16020065","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}